Sequential radiotherapy and adriamycin in the management of bronchogenic carcinoma: the question of additive toxicity

Conference · Wed Aug 01 04:00:00 EDT 1979 · Int. J. Radiat. Oncol., Biol. Phys.; (United States)

OSTI ID:5339501

Ruckdeschel, J C; Baxter, D H; McKneally, M F; Killam, D A; Lunia, S L; Horton, J

Intrapleural immunotherapy, radiotherapy and chemotherapy were employed in that sequence in 22 patients with Stage III non-oat cell bronchogenic carcinoma confined to the thorax. Seven patients received intrapleural BCG in a pilot study and 15 were randomized between intrapleural BCG and intrapleural saline. Isoniazid was begun on day 14 and irradiation (3000 rad in 10 fractions) to the primary lesion, mediastinum and ipsilateral supraclavicular nodes was started on day 21. One to two weeks following irradiation, CAMP chemotherapy was initiated (Cyclophosphamide 300 mg/M/sup 2/ iv, d. 1,8; Adriamycin 20 mg/M/sup 2/ iv, d. 1,8; Methotrexate 15 mg/M/sup 2/ iv, d. 1,8 and Procarbazine 100 mg/M/sup 2/ p.o., d. 1 to 10). Chemotherapy was given for a total of six months. Two patients expired prior to radiotherapy (1 tumor progression, 1 myocardial infarction) and 2 patients were lost to follow-up. Nausea, vomiting, alopecia and fatigue were universal side effects of the chemotherapy. Esophagitis occurred in 9 patients, 7 prior to and 2 after initiation of Adriamycin. In only one case did Adriamycin exacerbate a previous radiation esophagitis. No patient developed clinical radiation pneumonitis, although all had eventual radiation fibrosis. Congestive heart failure occurred in 1 patient with known valvular heart disease and responded to diuretics. Three patients developed localized herpes zoster infections. One patient developed radiation myelitis one year after initiating therapy and six months after completing all chemotherapy. The major side effect was leukopenia with relative platelet sparing. Although significant morbidity was encountered in this primarily older patient population (mean age 64.8 years) recall reactions involving irradiated intrathoracic structures were not a significant clinical problem.

• Research Organization: Albany Medical Coll., NY
• OSTI ID: 5339501
• Conference Information: Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Journal Volume: 5:8
• Country of Publication: United States
• Language: English

Related Subjects

550603 -- Medicine-- External Radiation in Therapy-- (1980-)
560151* -- Radiation Effects on Animals-- Man
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ALKYLATING AGENTS
ANEMIAS
ANTIBIOTICS
ANTIMETABOLITES
ANTIMITOTIC DRUGS
BIOLOGICAL EFFECTS
BIOLOGICAL RADIATION EFFECTS
CARCINOMAS
CHEMOTHERAPY
DISEASES
DOXORUBICIN
DRUGS
ENDOXAN
FRACTIONATED IRRADIATION
HEMIC DISEASES
IRRADIATION
LEUKOPENIA
MEDICINE
METHOTREXATE
NAUSEA
NEOPLASMS
NUCLEAR MEDICINE
PATHOLOGICAL CHANGES
PATIENTS
RADIATION EFFECTS
RADIOLOGY
RADIOTHERAPY
RESPIRATORY SYSTEM DISEASES
SIDE EFFECTS
SYMPTOMS
THERAPY
TOXICITY
VOMITING